Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Earlybird Health Ii Fund Gmbh & Co. Kg investment portfolio
Earlybird Health Ii Fund Gmbh & Co. Kg has made numerous investments in companies such as Prothea Technologies, Grey Wolf Therapeutics, and Portal Biotech within the Healthcare & Life Sciences sector.
vc
Portfolio
3
Team
0
Portfolio (3)
| Company | Sector | City | Source | Last confirmed on |
|---|---|---|---|---|
| Grey Wolf Therapeutics Limited Grey Wolf Therapeutics Limited is a clinical‑stage biotechnology company that develops antigen‑modulation therapies—small‑molecule drugs that alter the first step of T‑cell signaling—to treat cancer and autoimmune diseases. Its work focuses on research and experimental development of novel immuno‑oncology therapeutics. | Healthcare & Life Sciences | Abingdon | Confirmed | 2025-10-27 |
| Portal Biotech Limited PORTAL BIOTECH LIMITED develops innovative biotechnology solutions, including single-molecule protein sequencing instruments and cell engineering platforms, to advance healthcare. The company's products and services are aimed at research, clinical, biosecurity, and industrial applications, supporting areas such as drug discovery, precision medicine, and pathogen detection. | Healthcare & Life Sciences | Guildford | Confirmed | 2025-03-29 |
Shareholding changes (5)
Earlybird Health Ii Fund Gmbh & Co. Kg's positions across portfolio companies2026
- SERIES A SHARES OF 0.001 314,285 → 571,427
- SERIES A1 PREFERRED 0 → 20,749
Articles (2)
- Earlybird Health and Merieux Equity Partners increase Prothea stakes14 Jul 2026Prothea Technologies
- 18 Jun 2026